ATOS
Price
$0.98
Change
-$0.05 (-4.85%)
Updated
Oct 17 closing price
Capitalization
126.54M
30 days until earnings call
LQDA
Price
$22.48
Change
-$0.70 (-3.02%)
Updated
Oct 17 closing price
Capitalization
1.94B
24 days until earnings call
Interact to see
Advertisement

ATOS vs LQDA

Header iconATOS vs LQDA Comparison
Open Charts ATOS vs LQDABanner chart's image
Atossa Therapeutics
Price$0.98
Change-$0.05 (-4.85%)
Volume$1.21M
Capitalization126.54M
Liquidia
Price$22.48
Change-$0.70 (-3.02%)
Volume$1.92M
Capitalization1.94B
ATOS vs LQDA Comparison Chart in %
ATOS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LQDA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ATOS vs. LQDA commentary
Oct 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATOS is a Hold and LQDA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 18, 2025
Stock price -- (ATOS: $0.98 vs. LQDA: $22.48)
Brand notoriety: ATOS and LQDA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATOS: 133% vs. LQDA: 73%
Market capitalization -- ATOS: $126.54M vs. LQDA: $1.94B
ATOS [@Biotechnology] is valued at $126.54M. LQDA’s [@Biotechnology] market capitalization is $1.94B. The market cap for tickers in the [@Biotechnology] industry ranges from $106.87B to $0. The average market capitalization across the [@Biotechnology] industry is $2.06B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATOS’s FA Score shows that 1 FA rating(s) are green whileLQDA’s FA Score has 1 green FA rating(s).

  • ATOS’s FA Score: 1 green, 4 red.
  • LQDA’s FA Score: 1 green, 4 red.
According to our system of comparison, both ATOS and LQDA are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATOS’s TA Score shows that 6 TA indicator(s) are bullish while LQDA’s TA Score has 5 bullish TA indicator(s).

  • ATOS’s TA Score: 6 bullish, 5 bearish.
  • LQDA’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, ATOS is a better buy in the short-term than LQDA.

Price Growth

ATOS (@Biotechnology) experienced а -9.30% price change this week, while LQDA (@Biotechnology) price change was -3.06% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.56%. For the same industry, the average monthly price growth was +15.88%, and the average quarterly price growth was +79.09%.

Reported Earning Dates

ATOS is expected to report earnings on Nov 17, 2025.

LQDA is expected to report earnings on Nov 11, 2025.

Industries' Descriptions

@Biotechnology (+1.56% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
LQDA($1.94B) has a higher market cap than ATOS($127M). LQDA YTD gains are higher at: 91.156 vs. ATOS (3.760). ATOS has higher annual earnings (EBITDA): -29.97M vs. LQDA (-133.4M). LQDA has more cash in the bank: 173M vs. ATOS (57.9M). ATOS has less debt than LQDA: ATOS (0) vs LQDA (200M). LQDA has higher revenues than ATOS: LQDA (19.3M) vs ATOS (0).
ATOSLQDAATOS / LQDA
Capitalization127M1.94B7%
EBITDA-29.97M-133.4M22%
Gain YTD3.76091.1564%
P/E RatioN/AN/A-
Revenue019.3M-
Total Cash57.9M173M33%
Total Debt0200M-
FUNDAMENTALS RATINGS
ATOS vs LQDA: Fundamental Ratings
ATOS
LQDA
OUTLOOK RATING
1..100
7712
VALUATION
overvalued / fair valued / undervalued
1..100
22
Undervalued
90
Overvalued
PROFIT vs RISK RATING
1..100
10019
SMR RATING
1..100
97100
PRICE GROWTH RATING
1..100
4139
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ATOS's Valuation (22) in the Medical Specialties industry is significantly better than the same rating for LQDA (90) in the Pharmaceuticals Major industry. This means that ATOS’s stock grew significantly faster than LQDA’s over the last 12 months.

LQDA's Profit vs Risk Rating (19) in the Pharmaceuticals Major industry is significantly better than the same rating for ATOS (100) in the Medical Specialties industry. This means that LQDA’s stock grew significantly faster than ATOS’s over the last 12 months.

ATOS's SMR Rating (97) in the Medical Specialties industry is in the same range as LQDA (100) in the Pharmaceuticals Major industry. This means that ATOS’s stock grew similarly to LQDA’s over the last 12 months.

LQDA's Price Growth Rating (39) in the Pharmaceuticals Major industry is in the same range as ATOS (41) in the Medical Specialties industry. This means that LQDA’s stock grew similarly to ATOS’s over the last 12 months.

LQDA's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as ATOS (100) in the Medical Specialties industry. This means that LQDA’s stock grew similarly to ATOS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATOSLQDA
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
82%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
78%
Bearish Trend 1 day ago
88%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
90%
MACD
ODDS (%)
Bearish Trend 1 day ago
89%
Bullish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
83%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
80%
Bearish Trend 1 day ago
85%
Advances
ODDS (%)
Bullish Trend 10 days ago
81%
Bullish Trend 3 days ago
85%
Declines
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 17 days ago
83%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
80%
Bullish Trend 1 day ago
82%
Aroon
ODDS (%)
Bullish Trend 1 day ago
76%
Bearish Trend 1 day ago
78%
View a ticker or compare two or three
Interact to see
Advertisement
ATOS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LQDA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
DENI16.440.04
+0.24%
Denali Bancorp Inc
AMBZ54.90N/A
N/A
American Business Bank (Los Angeles, CA)
ICHGF119.53N/A
N/A
InterContinental Hotels Group Plc
MDIKF18.29N/A
N/A
Modec Inc.
RTGC0.37N/A
N/A
Ridder Titan Genesis Corp.

ATOS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATOS has been loosely correlated with NRIX. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if ATOS jumps, then NRIX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATOS
1D Price
Change %
ATOS100%
-4.89%
NRIX - ATOS
43%
Loosely correlated
-1.89%
AXON - ATOS
42%
Loosely correlated
+2.84%
PDSB - ATOS
41%
Loosely correlated
-2.04%
RLAY - ATOS
40%
Loosely correlated
-0.31%
RGNX - ATOS
40%
Loosely correlated
-4.94%
More

LQDA and

Correlation & Price change

A.I.dvisor indicates that over the last year, LQDA has been loosely correlated with TPST. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if LQDA jumps, then TPST could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LQDA
1D Price
Change %
LQDA100%
-3.02%
TPST - LQDA
34%
Loosely correlated
-8.57%
NUVL - LQDA
33%
Poorly correlated
+2.32%
KYMR - LQDA
33%
Poorly correlated
-1.04%
AXON - LQDA
32%
Poorly correlated
+2.84%
ATOS - LQDA
31%
Poorly correlated
-4.89%
More